Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Merck
Farmers Insurance
McKinsey
Julphar
Boehringer Ingelheim
US Army
Teva
UBS

Generated: November 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020943

« Back to Dashboard

NDA 020943 describes VERELAN PM, which is a drug marketed by Recro Gainesville and is included in one NDA. It is available from two suppliers. Additional details are available on the VERELAN PM profile page.

The generic ingredient in VERELAN PM is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.
Summary for 020943
Tradename:VERELAN PM
Applicant:Recro Gainesville
Ingredient:verapamil hydrochloride
Patents:0
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 020943
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943 NDA Kremers Urban Pharmaceuticals Inc. 62175-485 62175-485-37 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (62175-485-37)
VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943 NDA Kremers Urban Pharmaceuticals Inc. 62175-486 62175-486-37 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (62175-486-37)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength100MG
Approval Date:Nov 25, 1998TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength200MG
Approval Date:Nov 25, 1998TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength300MG
Approval Date:Nov 25, 1998TE:ABRLD:Yes

Expired US Patents for NDA 020943

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Recro Gainesville VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-001 Nov 25, 1998 ➤ Sign Up ➤ Sign Up
Recro Gainesville VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-003 Nov 25, 1998 ➤ Sign Up ➤ Sign Up
Recro Gainesville VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-002 Nov 25, 1998 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Fuji
Daiichi Sankyo
Citi
Teva
Harvard Business School
Merck
US Department of Justice
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.